News
UCBJF
341.00
NaN%
--
Goldman Sachs Keeps Their Buy Rating on UCB SA (0NZT)
TipRanks · 2d ago
Kepler Capital Sticks to Their Hold Rating for UCB SA (0NZT)
TipRanks · 5d ago
Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 6d ago
UCB SA Non-GAAP EPS of €9.99, revenue of €7.74B; introduces FY26 outlook
Seeking Alpha · 02/26 06:51
UCB initiated with an Outperform at Wolfe Research
TipRanks · 02/23 21:21
Barclays Keeps Their Buy Rating on UCB SA (0NZT)
TipRanks · 02/23 11:25
UCB SA (0NZT) Gets a Buy from UBS
TipRanks · 02/19 10:56
UCB SA (0NZT) Receives a Buy from Barclays
TipRanks · 02/16 14:05
UCB price target raised to EUR 304 from EUR 255 at Goldman Sachs
TipRanks · 02/16 11:25
Barclays Keeps Their Buy Rating on UCB SA (0NZT)
TipRanks · 02/09 07:25
Barclays Keeps Their Buy Rating on UCB SA (0NZT)
TipRanks · 02/04 11:36
UCB SA (0NZT) Receives a Hold from Kepler Capital
TipRanks · 02/04 01:47
Berenberg Bank Remains a Buy on UCB SA (0NZT)
TipRanks · 02/02 06:25
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
Benzinga · 01/28 10:51
Barclays Remains a Buy on UCB SA (0NZT)
TipRanks · 01/26 09:46
Barclays Remains a Buy on UCB SA (0NZT)
TipRanks · 01/19 09:16
Berenberg Bank Sticks to Their Buy Rating for UCB SA (0NZT)
TipRanks · 01/08 06:55
UCB price target raised to EUR 310 from EUR 270 at Barclays
TipRanks · 01/06 18:50
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
Benzinga · 01/06 18:42
UCB SA (0NZT) Gets a Buy from UBS
TipRanks · 12/15/2025 09:47
More
Webull provides a variety of real-time UCBJF stock news. You can receive the latest news about Ucb Sa through multiple platforms. This information may help you make smarter investment decisions.
About UCBJF
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.